Cardiff Oncology (CRDF) Prices 6.5M Share Common Offering at $13.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
After-Hours Stock Movers 9/29: (CTIC) (JFIN) (CMTL) Higher; (FCEL) (PRGS) (MU) Lower (more...)
September 29, 2020 5:54 PM EDTToday's After-Hours Stock Movers
CTI BioPharma Corp. (Nasdaq: CTIC) 167% HIGHER; announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration, the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count less than 50 x 109/L). The NDA will be based on the available data from the Company's completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 dose-ranging trial. The FDA has agreed to a... More
Cardiff Oncology (CRDF) Announces Proposed Common Share Offering
September 29, 2020 4:04 PM EDTCardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, announced today that it has commenced an underwritten public... More
